Latest News about RHHBY
Recent news which mentions RHHBY
Roche's $50 Billion US Investment Commitment Includes New Facilities, 12,000 Jobs, Expanded R&D Hubs As Drug Tariffs Loom
April 22, 2025
Tickers
RHHBY
From Benzinga
From Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
April 11, 2025
From Benzinga
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
April 10, 2025
From Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
April 09, 2025
From Benzinga
From Motley Fool
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
April 04, 2025
From Benzinga
From Benzinga
From Benzinga
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
April 02, 2025
From Benzinga
From Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
March 19, 2025
From Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
March 18, 2025
From Motley Fool
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
March 12, 2025
From Motley Fool
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
March 12, 2025
From Benzinga
From Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
February 27, 2025
From Motley Fool
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
January 28, 2025
From Benzinga
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
January 27, 2025
From Benzinga
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants
January 21, 2025
From Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
January 16, 2025
From Benzinga
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
December 31, 2024
From Benzinga
Roche CEO Reassures No Job Cuts Despite Challenges: Report
December 30, 2024
From Benzinga
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
December 19, 2024
From Benzinga
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
December 18, 2024
From Benzinga
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
December 13, 2024
From Benzinga
From Benzinga
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
November 26, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.